Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Xuanbinh Pham

Vascular Surgery Orange, CA Medical Doctor

NPI 1003164112 CMS profile 1376213

1010 W La Veta Ave Ste 320, Orange, CA 92868

Open in the dashboard

General payments

$27,656

91 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Xuanbinh Pham of Orange, CA is reported in the CMS Open Payments database as having received $27,656 across 91 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 86th percentile of Vascular Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $6,586 16
2024 General $2,833 16
2023 General $1,625 12
2022 General $559 11
2021 General $549 22
2020 General $107 5
2019 General $15,396 9

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Xuanbinh Pham
  • Vascular Surgery median
  • Middle half of Vascular Surgery
  • National median

In program year 2025, general payments to Xuanbinh Pham were reported at $6,586. Among 3,991 Vascular Surgery profiles paid that year, the median was $924 and the middle half received between $273 and $2,636.

Show as a table
Year Xuanbinh Pham Vascular Surgery median Middle half National median
2019 $15,396 $796 $226–$2,363 $163
2020 $107 $348 $118–$1,110 $114
2021 $549 $471 $158–$1,421 $132
2022 $559 $725 $222–$2,183 $149
2023 $1,625 $836 $257–$2,440 $160
2024 $2,833 $909 $252–$2,619 $164
2025 $6,586 $924 $273–$2,636 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic Vascular, Inc. $14,856 6 payments
  2. AngioDynamics, Inc. $8,293 3 payments
  3. W. L. Gore & Associates, Inc. $1,345 8 payments
  4. Penumbra, Inc. $863 13 payments
  5. Medtronic, Inc. $425 20 payments
  6. Abbott Laboratories $345 10 payments
  7. Cook Medical LLC $303 1 payment
  8. Silk Road Medical, Inc. $241 6 payments
  9. Koya Medical, Inc. $238 1 payment
  10. Reflow Medical Inc $191 5 payments
  11. Other $556 18 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Grant $14,886 3 payments
  2. Long term medical supply or device loan $8,267 2 payments
  3. Food and Beverage $3,112 81 payments
  4. Travel and Lodging $1,130 3 payments
  5. Education $262 2 payments
Products named General payments · program years 2019–2025
  1. Endurant Aortic Stent Grafts $14,640 5 payments
  2. Auryon Laser System 100-120 Vac Cv $6,000 1 payment
  3. Auryon Laser System 100-120 Vac Et $2,267 1 payment
  4. GORE TAG Thoracic Endoprosthesis $745 3 payments
  5. GORE TAG Thoracic Branch Endoprosthesis $530 2 payments
  6. Indigo System $519 6 payments
  7. Endurant Aortic Stent Grafts $256 6 payments
  8. Dayspring $238 1 payment
  9. ENROUTE Transcarotid Neuroprotection System $209 5 payments
  10. ENROUTE Transcarotid Stent $209 5 payments
  11. Other $1,917 65 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

119

Median for General Surgery: 59

Drug cost

$27,339

Median for General Surgery: $393

Branded share of claims

68.9%

Median for General Surgery: 28.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 39 $26,526
Clopidogrel Clopidogrel Bisulfate Brand 43 $397
Cilostazol Generic 14 $374
Oxycodone Hcl Generic 23 $41

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 15,891 Part D prescribers listed as General Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 114 billing codes

Paid by Medicare

$853,740

Medicare's payments for the services billed

Medicare patients

782

Average age 75

Services billed

2,780

390 women, 392 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 56%
Chronic kidney disease 53%
Diabetes 49%
Ischemic heart disease 47%
Heart failure 37%
Atrial fibrillation 30%
Depression 29%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

91 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular Surgery in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record